Associations between C-reactive protein-triglyceride glucose index combined with anthropometric indices and mortality risk in individuals with cardiovascular-kidney-liver-metabolic syndrome: a national cohort study Authors: Yeshen Zhang, Xinyue Gao, Xianglin Long, Yixuan Li, Weiwu Xiong, Shan Tu, Wenzhi Luo, Xu Deng, Lixiong Zeng, Fei Ye, Xiaoyan Wang, Zhihui Zhang Published: 2026 ABSTRACT BackgroundC-reactive protein-triglyceride glucose index (CTI) combined with anthropometric indices serve as integrative markers of insulin resistance, inflammation, and visceral obesity, exerting a detrimental effect on prognosis. However, the prognostic significance of CTI-anthropometric indices in individuals with cardiovascular-kidney-liver-metabolic (CKLM) syndrome remains uncertain. This study was conducted to elucidate the relationships between the CTI-anthropometric indices and mortality risk in this population.MethodsThis study included 14,203 individuals with CKLM syndrome from the National Health and Nutrition Examination Survey (NHANES, 1999–2018). Kaplan–Meier curve analyses, Cox proportional hazards models, Fine-Gray competing risk models, and restricted cubic spline (RCS) models were performed to evaluate the relationships of CTI-anthropometric indices with cardiovascular mortality and all-cause mortality. Receiver operating characteristic (ROC) curves were used to compare the predictive performance of CTI-anthropometric indices. Subgroup and sensitivity analyses were conducted to verify the robustness of the results.ResultsDuring a median follow-up period of 11.42 years, there were 772 cardiovascular deaths and 2,424 all-cause deaths. Kaplan‒Meier curve analyses indicated the lowest survival rate in the highest quartile of CTI-anthropometric indices (Log-rank p < 0.001). Multivariable Cox regression analyses revealed that CTI-anthropometric indices in the highest quartile were associated with an increased risk of cardiovascular mortality and all-cause mortality, compared with the lowest quartile. The Fine-Gray competing risk models also demonstrated that CTI-anthropometric indices were independently associated with cardiovascular mortality. The RCS results showed a linear or non-linear association of CTI-anthropometric indices with cardiovascular mortality and all-cause mortality. ROC curve analyses indicated that CTI-a body shape index (CTI-ABSI) exhibited preferred predictive performance for mortality risk at 1-, 5-, and 10-year time points compared to other CTI-anthropometric indices. Subgroup and sensitivity analyses confirmed the robustness of the results of CTI-ABSI.ConclusionElevated CTI-anthropometric indices were independently associated with increased mortality risk in individuals with CKLM syndrome, with CTI-ABSI emerging as the preferred predictor of mortality risk. These findings provide an approach for enhancing risk discrimination and stratification in individuals with CKLM syndrome.Clinical trial numberNot applicable.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12902-026-02366-z. Introduction In 2023, the American Heart Association introduced the concept of Cardiovascular-Kidney-Metabolic (CKM) syndrome, which encompasses modifiable risk factors that highlight the complex interrelationships among metabolic disorders, chronic kidney disease (CKD), and cardiovascular disease (CVD) [1]. However, in individuals with CKM syndrome, metabolic dysfunction–associated steatotic liver disease (MASLD) is prevalent and serves as both a contributor to and a consequence of metabolic dysfunction [2]. Consequently, a growing body of evidence supports the expansion of the CKM framework to incorporate MASLD, thereby establishing a cardiovascular-kidney-liver-metabolic (CKLM) syndrome [2–4]. A recent study has revealed that between 2007 and 2018, the proportion of adults in the United States with two or more CKLM conditions increased from 32.4% to 55.6% [5]. Notably, compared to patients without CKLM syndrome, those with CKLM syndrome exhibited a threefold increase in the risk of cardiovascular mortality and a twofold increase in the risk of all-cause mortality [5, 6]. Therefore, it is imperative to undertake early risk stratification for this population and implement proactive prevention. A multi-dimensional assessment approach may enhance the prognostic accuracy for stratifying mortality risk. Insulin resistance and systemic inflammation have been identified as the core mechanisms in the development of CKM syndrome and MASLD [1, 7]. Consequently, C-reactive protein–triglyceride–glucose index (CTI) was constructed to undertake early risk stratification in individuals with CKM syndrome or MASLD. Recent studies found that higher CTI levels were significantly associated with an increased risk of CVD and mortality in individuals with CKM syndrome [8, 9]. Furthermore, Jin et al. demonstrated that CTI levels exhibited a nonlinear association with the presence of MASLD, and elevated CTI was correlated with increased risks of all-cause and cardiovascular mortality among participants with MASLD [10]. These findings underscore the clinical utility of CTI in the risk stratification of cardiometabolic disease. Nevertheless, CTI did not incorporate the assessment of visceral adipose tissue accumulation, which is regarded as an upstream driver in the development of CKLM syndrome [4]. Visceral adipose tissue directly contributes to the exacerbation of insulin resistance, hepatic steatosis, and atherosclerosis by releasing free fatty acids, proinflammatory cytokines, and adipokines [11, 12]. Previous study also demonstrated that the co-occurrence of MASLD and obesity represented the most prevalent phenotypes of CKLM syndrome in the United States [5]. Considering the well-established mechanistic connections between visceral obesity, insulin resistance, and systemic inflammation in CKLM syndrome, examining the comprehensive biomarkers related to these pathways holds considerable clinical importance for risk stratification. Numerous anthropometric indices have been devised to better characterize visceral obesity and fat distribution, including the waist circumference (WC), body mass index (BMI), waist-to-height Ratio (WHtR), body roundness index (BRI), weight-adjusted waist index (WWI), and a body shape index (ABSI). Several studies have confirmed that the integration of the triglyceride-glucose index (TyG) with anthropometric indices improves risk stratification for various diseases, including myocardial infarction, MASLD, metabolic syndrome, cardiometabolic multimorbidity, and CKM syndrome [13–17]. A recent study found that the integration of CTI and BRI is the most efficacious approach for identifying and reclassifying hypertension risk, compared to other CTI-anthropometric indices [18]. However, the relationship between CTI-anthropometric indices and mortality risk in individuals with CKLM syndrome remains unknown. In light of the above, we conducted a study utilizing the National Health and Nutrition Examination Survey (NHANES) database to investigate the relationships between CTI-anthropometric indices and mortality risk among populations with CKLM syndrome, to provide new perspectives on the biomarkers of risk stratification for such populations. Methods Study design and population This cohort study was conducted utilizing data from the NHANES in the United States, spanning the years 1999 to 2018 (https://www.cdc.gov/nchs/nhanes). The NHANES project was approved by the Ethics Review Board of the National Center for Health Statistics, and written informed consent had already been received from each participant. The present study was conducted in accordance with the Declaration of Helsinki. The exclusion criteria of this study were as follows: (1) participants aged < 18 years; (2) participants with missing diagnostic data of CKM syndrome and MALSD; (3) participants without CTI-anthropometric indices; (4) women participants with pregnant status; (5) participants with no applicable follow-up data. The detailed flowchart is shown in Supplementary Figure S1. Definition of CKLM stages Following the definition of previous studies, CKLM syndrome was classified into 5 stages in this study [2, 3]. Briefly, participants in stage 0 had a normal BMI and WC and did not meet the criteria for other stages; participants in stage 1 had an elevated BMI, an elevated WC, or prediabetes; participants in stage 2 had metabolic risk factors, moderate-to-high-risk CKD stage, or MASLD with fibrosis-4 index (FIB-4) <1.3; participants in stage 3 were at a very high-risk CKD stage, had a high-predicted 10-year CVD risk, or had MASLD with FIB-4 ≥ 1.3; participants in stage 4 had self-reported CVD. Stages 0, 1, and 2 are classified as non-advanced CKLM syndrome, whereas Stages 3 and 4 are categorized as advanced CKLM syndrome. More detailed staging criteria are provided in Supplementary Table S1. Definition of CTI-anthropometric Indices The CTI-anthropometric indices examined in this study include CTI-WC, CTI-BMI, CTI-WHtR, CTI-BRI, CTI-WWI, and CTI-ABSI. The CTI and CTI-anthropometric indices were calculated for each participant using the following formula:CTI = 0.412 × Ln (C-reactive protein [CRP, mg/dl]) + Ln (triglyceride [TG, mg/dl] × fasting blood glucose [FBG, mg/dl])/2CTI-WC = CTI × WC (cm)CTI-BMI = CTI × Weight (kg)/Height (m)2CTI-WHtR = CTI × WC (cm)/Height (cm)CTI-BRI = CTI × (364.2 - 365.5 × [1 - π−2 × WC (m)2 × Height (m)−2]1/2)CTI-WWI = CTI × WC (cm)/Weight (kg)1/2CTI-ABSI = CTI × WC (m) × BMI-2/3 × Height (m)-1/2 CTI = 0.412 × Ln (C-reactive protein [CRP, mg/dl]) + Ln (triglyceride [TG, mg/dl] × fasting blood glucose [FBG, mg/dl])/2 CTI = 0.412 × Ln (C-reactive protein [CRP, mg/dl]) + Ln (triglyceride [TG, mg/dl] × fasting blood glucose [FBG, mg/dl])/2 CTI-WC = CTI × WC (cm) CTI-WC = CTI × WC (cm) CTI-BMI = CTI × Weight (kg)/Height (m)2 CTI-BMI = CTI × Weight (kg)/Height (m)2 CTI-WHtR = CTI × WC (cm)/Height (cm) CTI-WHtR = CTI × WC (cm)/Height (cm) CTI-BRI = CTI × (364.2 - 365.5 × [1 - π−2 × WC (m)2 × Height (m)−2]1/2) CTI-BRI = CTI × (364.2 - 365.5 × [1 - π−2 × WC (m)2 × Height (m)−2]1/2) CTI-WWI = CTI × WC (cm)/Weight (kg)1/2 CTI-WWI = CTI × WC (cm)/Weight (kg)1/2 CTI-ABSI = CTI × WC (m) × BMI-2/3 × Height (m)-1/2 CTI-ABSI = CTI × WC (m) × BMI-2/3 × Height (m)-1/2 Assessment of mortality The cardiovascular mortality and all-cause mortality of the follow-up population were determined using NHANES public-use linked mortality files. After physical examinations at the mobile examination center (MEC), follow-up commenced until the date of death or the censored date (December 31, 2019). Cardiovascular mortality was defined as the deaths attributed to heart diseases (I00–I09, I11, I13, I20–I51) and cerebrovascular diseases (I60–I69) by the International Classification of Diseases, 10th Clinical Modification system. All-cause mortality refers to deaths attributed to all specified and unknown causes. Data collection According to previous study, baseline covariates were extracted from the self-reported questionnaires and MEC examinations. [19] Demographic characteristics included age, gender, race, educational level, and family poverty income ratio. Lifestyle behaviors encompassed smoking status, drinking status, and physical activity time. The physiological and anthropometric measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), weight, height, WC, and BMI. The laboratory assessments were collected, including glycosylated hemoglobin A1c (HbA1c), FBG, TG, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), serum albumin (ALB), and CRP (values below the detection limit were already imputed as 0.01 mg/dl by NHANES). Information on medication use included antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. The information on comorbidities, including hypertension, dyslipidemia, diabetes, CKD, CVD, and cancer, was collected. Hypertension was identified by SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, self-reported history of hypertension, or the use of antihypertensive agents. Diabetes was defined as FBG ≥ 7.0 mmol/L, HbA1c ≥ 6.5%, self-reported history of diabetes, or use of antihyperglycemic agents. Dyslipidemia was identified by HDL-C < 1.0 mmol/L, LDL-C ≥ 3.62 mmol/L, and TG ≥ 1.70 mmol/L, self-reported history of hyperlipidemia, or use of lipid-lowering agents. CVD was defined as a self-report history of congestive heart failure, coronary heart disease, angina pectoris, myocardial infarction, or stroke. Cancer was determined based on self-reported survey interviews. In addition, the Chronic Kidney Disease Epidemiology Collaboration equation was utilized to compute the estimated glomerular filtration rate (eGFR), and the eGFR of 15–59 mL/min/1.73 m2 or self-report history of CKD was considered to have CKD [20]. Statistical analysis Given the complex sampling design of NHANES, the weights, clustering, and stratification were incorporated into the present study. Covariates with missing data were imputed using a multilevel approach developed for survey data, with missing rates ranging from 0.1% to 23.1% [21, 22]. A Gibbs sampling method was employed to produce 10 imputed datasets, following a burn-in period of 500 iterations and 100 updates, to ensure stochastic independence among the imputed datasets. The baseline characteristics were stratified by stages of CKLM syndrome and quartiles of CTI-anthropometric indices, with continuous variables presented as median (interquartile range) and categorical variables as frequency (percentage). The Kruskal–Wallis rank sum test was employed for continuous variables, while the chi-square test was applied to categorical variables. The Kaplan–Meier curve analysis and log-rank test were conducted to assess differences in survival probabilities. To evaluate the independent associations between CTI-anthropometric indices and mortality risk, a multivariable Cox proportional hazards model was employed. The multivariable model was adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, SBP, HbA1c, LDL-C, ALT, AST, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. Afterward, a Fine-Gray competing risk model analysis was performed, considering the non-cardiovascular mortality as a competing event. Restricted cubic spline (RCS) analysis with four knots at the 5th, 35th, 65th, and 95th centiles was developed to evaluate the dose-response relationship between CTI-anthropometric indices and mortality risk. Moreover, the discriminatory ability of CTI-anthropometric indices for predicting cardiovascular mortality and all-cause mortality at different time points was evaluated using time-dependent ROC receiver operating characteristic (ROC) curve analysis, and the area under the ROC curve (AUC) was calculated. Subgroup and interaction analyses were carried out according to age, gender, race, FIB-4 index, hypertension, diabetes, dyslipidemia, and CKLM syndrome to assess the consistency of the association between CTI-ABSI and mortality risk across different subgroups. Sensitivity analyses were conducted to test the robustness of the results of CTI-ABSI by: (1) excluding deaths occurring or censored within the first 2 years of follow-up; (2) excluding participants with a history of CVD; (3) excluding participants with a history of cancer; (4) excluding participants aged over 75 years; and (5) excluding participants with missing any key covariates. All analyses were conducted with R statistical software (version 4.4.3; the R Foundation for Statistical Computing, Vienna, Austria). A two-sided P lower than 0.05 was considered statistically significant. Results Baseline characteristics This study finally included 14,203 participants with CKLM syndrome, of whom 49.55% were female, with a median age of 49 years. According to CKLM stages, the proportions of participants in stages 0 to 4 were 4.51%, 7.40%, 60.28%, 14.32%, and 13.49%, respectively. As shown in Table 1, significant differences were observed across CKLM stages in demographic characteristics, clinical indicators, medication use, and comorbidities (all p < 0.001). With the progression from CKLM stage 0 to stage 3, the levels of CTI-anthropometric indices exhibited a gradual increase. Additionally, we conducted a baseline characteristic analysis based on the quartiles of CTI-anthropometric indices (Supplementary Table S2–S7). The results revealed statistically significant differences in demographic characteristics, clinical indicators, medication use, and comorbidities among the quartile groups of CTI-anthropometric indices.Table 1Baseline characteristics according to the stages of CKLM syndromeCharacteristicsOverall(n = 14,203)CKLM stagesPvalueStage 0(n = 641)Stage 1(n = 1,051)Stage 2(n = 8,561)Stage 3(n = 2,034)Stage 4(n = 1,916)Age, years49.00(38.00, 61.00)40.00(35.00, 47.00)43.00(36.00, 50.00)46.48(36.00, 56.00)66.00(57.00, 73.00)65.00(56.00, 75.00)<0.001Gender, n (%)<0.001 Male7,229 (50.45)219 (31.80)448 (43.55)4,222 (50.50)1,241 (61.50)1,099 (55.23) Female6,974 (49.55)422 (68.20)603 (56.45)4,339 (49.50)793 (38.50)817 (44.77)Race, n (%)<0.001 Mexican American2,848 (7.95)69 (3.86)233 (9.87)1,892 (8.98)414 (6.46)240 (4.15) Non-Hispanic Black2,758 (10.13)101 (7.36)215 (10.92)1,675 (10.27)384 (9.51)383 (11.02) Non-Hispanic White6,408 (70.34)369 (77.95)423 (67.32)3,573 (68.28)981 (76.14)1,062 (74.68) Other race2,189 (11.58)102 (10.83)180 (11.89)1,421 (12.48)255 (7.89)231 (10.15)Education, n (%)<0.001 Less than high school1,992 (6.70)46 (4.25)104 (5.41)1,080 (5.86)412 (9.95)350 (10.96) High school grad or equivalent5,457 (36.48)173 (23.85)352 (29.54)3,342 (37.36)777 (37.40)813 (43.36) Some college or above6,754 (56.81)422 (71.90)595 (65.05)4,139 (56.78)845 (52.65)753 (45.68)Smoking status, n (%)<0.001 Never7,279 (50.48)374 (56.10)640 (59.05)4,624 (52.37)916 (43.10)725 (36.39) Former3,922 (28.16)115 (19.94)217 (24.06)1,988 (24.94)809 (42.48)793 (40.96) Now3,002 (21.36)152 (23.96)194 (16.89)1,949 (22.69)309 (14.42)398 (22.64)Drinking status, n (%)<0.001 Never4,725 (28.72)163 (22.11)326 (25.01)2,785 (28.35)724 (31.68)727 (34.82) 1–5 drinks/month6,472 (45.64)305 (45.96)468 (45.68)4,004 (46.68)835 (39.83)860 (45.15) 5–10 drinks/month1,006 (8.64)63 (11.88)100 (10.67)650 (8.86)106 (6.90)87 (5.53) ≥10 drinks/month2,000 (17.01)110 (20.04)157 (18.64)1,122 (16.11)369 (21.59)242 (14.50)Physical activity time, min/week120.00(0.00, 360.00)214.21(45.50, 476.00)180.00(21.00, 480.00)120.00(0.00, 360.00)90.00(0.00, 300.00)60.61(0.00, 240.00)<0.001Family poverty income ratio3.15(1.64, 5.00)3.97(2.06, 5.00)3.59(1.92, 5.00)3.22(1.66, 5.00)2.99(1.59, 5.00)2.25(1.25, 4.25)<0.001BMI, kg/m228.74(25.01, 33.20)22.40(20.86, 23.69)26.30(24.41, 28.30)29.40(25.76, 34.01)31.30(28.35, 34.66)28.99(25.39, 33.50)<0.001SBP, mmHg121.00(111.00, 132.00)108.66(103.00, 116.00)112.00(105.00, 119.00)121.00(113.00, 132.00)131.00(119.00, 144.00)127.00(115.00, 142.00)<0.001DBP, mmHg72.00(65.00, 79.00)68.00(62.00, 73.00)70.00(65.00, 75.00)73.00(66.00, 80.00)71.00(63.00, 79.00)68.00(59.00, 77.00)<0.001FBG, mmol/L5.55(5.16, 6.07)5.03(4.79, 5.24)5.44(5.07, 5.72)5.55(5.17, 6.00)6.01(5.55, 6.88)5.88(5.38, 6.84)<0.001HbA1c, %5.40(5.20, 5.70)5.10(5.00, 5.30)5.30(5.10, 5.50)5.40(5.20, 5.70)5.70(5.40, 6.10)5.70(5.40, 6.20)<0.001TG, mmol/L1.31(0.90, 1.92)0.78(0.62, 0.98)0.86(0.63, 1.10)1.42(0.99, 2.04)1.55(1.14, 2.18)1.43(0.99, 2.07)<0.001TC, mmol/L5.09(4.45, 5.79)4.65(4.22, 5.09)4.73(4.19, 5.15)5.28(4.63, 6.00)5.04(4.37, 5.74)4.71(3.98, 5.53)<0.001LDL-C, mmol/L3.05(2.46, 3.65)2.61(2.20, 3.00)2.77(2.38, 3.13)3.21(2.64, 3.83)2.92(2.33, 3.54)2.61(2.02, 3.34)<0.001HDL-C, mmol/L1.29(1.06, 1.58)1.66(1.40, 1.91)1.53(1.29, 1.76)1.24(1.03, 1.53)1.24(1.03, 1.54)1.23(1.03, 1.53)<0.001ALB, g/L42.00(40.00, 45.00)43.00(41.00, 45.00)43.00(41.00, 45.00)42.00(40.00, 45.00)42.00(40.00, 44.00)41.00(39.00, 44.00)<0.001ALT, IU/L22.00(17.00, 30.00)17.00(14.00, 21.48)18.00(15.00, 24.00)23.00(17.00, 32.00)24.00(18.00, 35.00)21.00(16.00, 28.00)<0.001AST, IU/L23.00(19.00, 27.00)21.00(18.00, 24.00)21.00(18.00, 25.00)22.00(19.00, 27.00)26.00(22.00, 34.00)23.00(19.00, 28.00)<0.001GGT, U/L21.00(15.00, 33.00)14.00(11.00, 18.00)16.00(12.00, 22.00)22.00(16.00, 34.00)27.00(18.00, 47.00)23.00(16.00, 36.00)<0.001CRP, mg/dl0.36(0.12, 1.11)0.10(0.04, 0.34)0.24(0.08, 0.78)0.38(0.14, 1.20)0.48(0.18, 1.60)0.46(0.17, 1.50)<0.001eGFR, mL/min/1.73 m294.09(80.03, 107.11)99.14(89.55, 110.27)99.68(88.09, 111.41)97.18(84.36, 108.95)80.02(65.29, 92.51)77.15(59.61, 92.61)<0.001Fatty liver index63.10(28.74, 86.59)7.78(5.06, 12.45)25.32(14.88, 39.34)67.68(37.26, 88.34)82.07(68.96, 92.46)69.69(37.66, 89.50)<0.001Fibrosis-4 index0.93(0.66, 1.32)0.82(0.64, 1.08)0.87(0.67, 1.12)0.82(0.59, 1.09)1.62(1.41, 2.01)1.45(1.02, 1.94)<0.001Hypertension, n (%)7,031 (44.12)0 (0.00)0 (0.00)3,848 (42.92)1,535 (72.73)1,648 (83.45)<0.001Diabetes, n (%)3,054 (16.29)0 (0.00)0 (0.00)1,453 (13.63)797 (34.16)804 (36.61)<0.001Dyslipidemia, n (%)9,907 (68.06)0 (0.00)0 (0.00)6,625 (78.71)1,614 (78.59)1,668 (87.63)<0.001CKD, n (%)1,155 (5.95)0 (0.00)0 (0.00)186 (2.10)415 (17.90)554 (25.33)<0.001CVD, n (%)1,916 (10.40)0 (0.00)0 (0.00)0 (0.00)0 (0.00)1,916 (100.00)<0.001Cancer, n (%)1,354 (9.83)32 (5.01)54 (6.51)552 (7.54)330 (18.06)386 (20.82)<0.001Antihypertensive agents use, n (%)5,292 (32.81)0 (0.00)0 (0.00)2,466 (28.12)1,292 (61.67)1,534 (77.40)<0.001Antihyperglycemic agents use, n (%)1,882 (9.75)0 (0.00)0 (0.00)822 (9.60)498 (24.48)562 (29.33)<0.001Lipid-lowering agents use, n (%)4,640 (29.87)0 (0.00)0 (0.00)2,177 (25.90)1,066 (52.10)1,397 (72.88)<0.001CTI4.31(3.81, 4.83)3.44(3.02, 3.94)3.86(3.36, 4.31)4.38(3.89, 4.86)4.56(4.12, 5.07)4.50(4.02, 5.01)<0.001CTI-WC432.44(354.56, 520.22)281.41(238.14, 320.25)348.05(298.69, 403.19)441.55(370.32, 527.07)495.24(440.24, 567.70)464.92(391.74, 551.71)<0.001CTI-BMI124.34(98.74, 154.49)76.56(65.73, 88.53)101.02(85.56, 117.26)128.68(104.10, 159.60)142.12(122.93, 167.53)129.54(106.33, 160.74)<0.001CTI-WHtR2.56(2.09, 3.10)1.66(1.42, 1.88)2.07(1.77, 2.39)2.60(2.17, 3.13)2.94(2.58, 3.40)2.76(2.32, 3.31)<0.001CTI-BRI1.35(0.08, 3.20)−0.83(−1.13, −0.44)0.22(−0.33, 0.88)1.44(0.29, 3.26)2.74(1.68, 4.41)2.01(0.68, 4.03)<0.001CTI-WWI47.54(40.72, 54.60)35.17(30.32, 40.11)40.63(34.75, 45.87)48.03(41.77, 54.57)52.51(46.75, 59.14)51.55(44.90, 58.56)<0.001CTI-ABSI3.52(3.07, 3.98)2.73(2.33, 3.12)3.03(2.66, 3.46)3.54(3.13, 3.98)3.86(3.44, 4.32)3.79(3.34, 4.26)<0.001Abbreviations: CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin A1c; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; CVD, cardiovascular disease; CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index. Continuous variables are expressed as median (interquartile range) and categorical variables as frequency (percentage) Table 1Baseline characteristics according to the stages of CKLM syndromeCharacteristicsOverall(n = 14,203)CKLM stagesPvalueStage 0(n = 641)Stage 1(n = 1,051)Stage 2(n = 8,561)Stage 3(n = 2,034)Stage 4(n = 1,916)Age, years49.00(38.00, 61.00)40.00(35.00, 47.00)43.00(36.00, 50.00)46.48(36.00, 56.00)66.00(57.00, 73.00)65.00(56.00, 75.00)<0.001Gender, n (%)<0.001 Male7,229 (50.45)219 (31.80)448 (43.55)4,222 (50.50)1,241 (61.50)1,099 (55.23) Female6,974 (49.55)422 (68.20)603 (56.45)4,339 (49.50)793 (38.50)817 (44.77)Race, n (%)<0.001 Mexican American2,848 (7.95)69 (3.86)233 (9.87)1,892 (8.98)414 (6.46)240 (4.15) Non-Hispanic Black2,758 (10.13)101 (7.36)215 (10.92)1,675 (10.27)384 (9.51)383 (11.02) Non-Hispanic White6,408 (70.34)369 (77.95)423 (67.32)3,573 (68.28)981 (76.14)1,062 (74.68) Other race2,189 (11.58)102 (10.83)180 (11.89)1,421 (12.48)255 (7.89)231 (10.15)Education, n (%)<0.001 Less than high school1,992 (6.70)46 (4.25)104 (5.41)1,080 (5.86)412 (9.95)350 (10.96) High school grad or equivalent5,457 (36.48)173 (23.85)352 (29.54)3,342 (37.36)777 (37.40)813 (43.36) Some college or above6,754 (56.81)422 (71.90)595 (65.05)4,139 (56.78)845 (52.65)753 (45.68)Smoking status, n (%)<0.001 Never7,279 (50.48)374 (56.10)640 (59.05)4,624 (52.37)916 (43.10)725 (36.39) Former3,922 (28.16)115 (19.94)217 (24.06)1,988 (24.94)809 (42.48)793 (40.96) Now3,002 (21.36)152 (23.96)194 (16.89)1,949 (22.69)309 (14.42)398 (22.64)Drinking status, n (%)<0.001 Never4,725 (28.72)163 (22.11)326 (25.01)2,785 (28.35)724 (31.68)727 (34.82) 1–5 drinks/month6,472 (45.64)305 (45.96)468 (45.68)4,004 (46.68)835 (39.83)860 (45.15) 5–10 drinks/month1,006 (8.64)63 (11.88)100 (10.67)650 (8.86)106 (6.90)87 (5.53) ≥10 drinks/month2,000 (17.01)110 (20.04)157 (18.64)1,122 (16.11)369 (21.59)242 (14.50)Physical activity time, min/week120.00(0.00, 360.00)214.21(45.50, 476.00)180.00(21.00, 480.00)120.00(0.00, 360.00)90.00(0.00, 300.00)60.61(0.00, 240.00)<0.001Family poverty income ratio3.15(1.64, 5.00)3.97(2.06, 5.00)3.59(1.92, 5.00)3.22(1.66, 5.00)2.99(1.59, 5.00)2.25(1.25, 4.25)<0.001BMI, kg/m228.74(25.01, 33.20)22.40(20.86, 23.69)26.30(24.41, 28.30)29.40(25.76, 34.01)31.30(28.35, 34.66)28.99(25.39, 33.50)<0.001SBP, mmHg121.00(111.00, 132.00)108.66(103.00, 116.00)112.00(105.00, 119.00)121.00(113.00, 132.00)131.00(119.00, 144.00)127.00(115.00, 142.00)<0.001DBP, mmHg72.00(65.00, 79.00)68.00(62.00, 73.00)70.00(65.00, 75.00)73.00(66.00, 80.00)71.00(63.00, 79.00)68.00(59.00, 77.00)<0.001FBG, mmol/L5.55(5.16, 6.07)5.03(4.79, 5.24)5.44(5.07, 5.72)5.55(5.17, 6.00)6.01(5.55, 6.88)5.88(5.38, 6.84)<0.001HbA1c, %5.40(5.20, 5.70)5.10(5.00, 5.30)5.30(5.10, 5.50)5.40(5.20, 5.70)5.70(5.40, 6.10)5.70(5.40, 6.20)<0.001TG, mmol/L1.31(0.90, 1.92)0.78(0.62, 0.98)0.86(0.63, 1.10)1.42(0.99, 2.04)1.55(1.14, 2.18)1.43(0.99, 2.07)<0.001TC, mmol/L5.09(4.45, 5.79)4.65(4.22, 5.09)4.73(4.19, 5.15)5.28(4.63, 6.00)5.04(4.37, 5.74)4.71(3.98, 5.53)<0.001LDL-C, mmol/L3.05(2.46, 3.65)2.61(2.20, 3.00)2.77(2.38, 3.13)3.21(2.64, 3.83)2.92(2.33, 3.54)2.61(2.02, 3.34)<0.001HDL-C, mmol/L1.29(1.06, 1.58)1.66(1.40, 1.91)1.53(1.29, 1.76)1.24(1.03, 1.53)1.24(1.03, 1.54)1.23(1.03, 1.53)<0.001ALB, g/L42.00(40.00, 45.00)43.00(41.00, 45.00)43.00(41.00, 45.00)42.00(40.00, 45.00)42.00(40.00, 44.00)41.00(39.00, 44.00)<0.001ALT, IU/L22.00(17.00, 30.00)17.00(14.00, 21.48)18.00(15.00, 24.00)23.00(17.00, 32.00)24.00(18.00, 35.00)21.00(16.00, 28.00)<0.001AST, IU/L23.00(19.00, 27.00)21.00(18.00, 24.00)21.00(18.00, 25.00)22.00(19.00, 27.00)26.00(22.00, 34.00)23.00(19.00, 28.00)<0.001GGT, U/L21.00(15.00, 33.00)14.00(11.00, 18.00)16.00(12.00, 22.00)22.00(16.00, 34.00)27.00(18.00, 47.00)23.00(16.00, 36.00)<0.001CRP, mg/dl0.36(0.12, 1.11)0.10(0.04, 0.34)0.24(0.08, 0.78)0.38(0.14, 1.20)0.48(0.18, 1.60)0.46(0.17, 1.50)<0.001eGFR, mL/min/1.73 m294.09(80.03, 107.11)99.14(89.55, 110.27)99.68(88.09, 111.41)97.18(84.36, 108.95)80.02(65.29, 92.51)77.15(59.61, 92.61)<0.001Fatty liver index63.10(28.74, 86.59)7.78(5.06, 12.45)25.32(14.88, 39.34)67.68(37.26, 88.34)82.07(68.96, 92.46)69.69(37.66, 89.50)<0.001Fibrosis-4 index0.93(0.66, 1.32)0.82(0.64, 1.08)0.87(0.67, 1.12)0.82(0.59, 1.09)1.62(1.41, 2.01)1.45(1.02, 1.94)<0.001Hypertension, n (%)7,031 (44.12)0 (0.00)0 (0.00)3,848 (42.92)1,535 (72.73)1,648 (83.45)<0.001Diabetes, n (%)3,054 (16.29)0 (0.00)0 (0.00)1,453 (13.63)797 (34.16)804 (36.61)<0.001Dyslipidemia, n (%)9,907 (68.06)0 (0.00)0 (0.00)6,625 (78.71)1,614 (78.59)1,668 (87.63)<0.001CKD, n (%)1,155 (5.95)0 (0.00)0 (0.00)186 (2.10)415 (17.90)554 (25.33)<0.001CVD, n (%)1,916 (10.40)0 (0.00)0 (0.00)0 (0.00)0 (0.00)1,916 (100.00)<0.001Cancer, n (%)1,354 (9.83)32 (5.01)54 (6.51)552 (7.54)330 (18.06)386 (20.82)<0.001Antihypertensive agents use, n (%)5,292 (32.81)0 (0.00)0 (0.00)2,466 (28.12)1,292 (61.67)1,534 (77.40)<0.001Antihyperglycemic agents use, n (%)1,882 (9.75)0 (0.00)0 (0.00)822 (9.60)498 (24.48)562 (29.33)<0.001Lipid-lowering agents use, n (%)4,640 (29.87)0 (0.00)0 (0.00)2,177 (25.90)1,066 (52.10)1,397 (72.88)<0.001CTI4.31(3.81, 4.83)3.44(3.02, 3.94)3.86(3.36, 4.31)4.38(3.89, 4.86)4.56(4.12, 5.07)4.50(4.02, 5.01)<0.001CTI-WC432.44(354.56, 520.22)281.41(238.14, 320.25)348.05(298.69, 403.19)441.55(370.32, 527.07)495.24(440.24, 567.70)464.92(391.74, 551.71)<0.001CTI-BMI124.34(98.74, 154.49)76.56(65.73, 88.53)101.02(85.56, 117.26)128.68(104.10, 159.60)142.12(122.93, 167.53)129.54(106.33, 160.74)<0.001CTI-WHtR2.56(2.09, 3.10)1.66(1.42, 1.88)2.07(1.77, 2.39)2.60(2.17, 3.13)2.94(2.58, 3.40)2.76(2.32, 3.31)<0.001CTI-BRI1.35(0.08, 3.20)−0.83(−1.13, −0.44)0.22(−0.33, 0.88)1.44(0.29, 3.26)2.74(1.68, 4.41)2.01(0.68, 4.03)<0.001CTI-WWI47.54(40.72, 54.60)35.17(30.32, 40.11)40.63(34.75, 45.87)48.03(41.77, 54.57)52.51(46.75, 59.14)51.55(44.90, 58.56)<0.001CTI-ABSI3.52(3.07, 3.98)2.73(2.33, 3.12)3.03(2.66, 3.46)3.54(3.13, 3.98)3.86(3.44, 4.32)3.79(3.34, 4.26)<0.001Abbreviations: CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin A1c; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; CVD, cardiovascular disease; CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index. Continuous variables are expressed as median (interquartile range) and categorical variables as frequency (percentage) Baseline characteristics according to the stages of CKLM syndrome 49.00 (38.00, 61.00) 40.00 (35.00, 47.00) 43.00 (36.00, 50.00) 46.48 (36.00, 56.00) 66.00 (57.00, 73.00) 65.00 (56.00, 75.00) 120.00 (0.00, 360.00) 214.21 (45.50, 476.00) 180.00 (21.00, 480.00) 120.00 (0.00, 360.00) 90.00 (0.00, 300.00) 60.61 (0.00, 240.00) 3.15 (1.64, 5.00) 3.97 (2.06, 5.00) 3.59 (1.92, 5.00) 3.22 (1.66, 5.00) 2.99 (1.59, 5.00) 2.25 (1.25, 4.25) 28.74 (25.01, 33.20) 22.40 (20.86, 23.69) 26.30 (24.41, 28.30) 29.40 (25.76, 34.01) 31.30 (28.35, 34.66) 28.99 (25.39, 33.50) 121.00 (111.00, 132.00) 108.66 (103.00, 116.00) 112.00 (105.00, 119.00) 121.00 (113.00, 132.00) 131.00 (119.00, 144.00) 127.00 (115.00, 142.00) 72.00 (65.00, 79.00) 68.00 (62.00, 73.00) 70.00 (65.00, 75.00) 73.00 (66.00, 80.00) 71.00 (63.00, 79.00) 68.00 (59.00, 77.00) 5.55 (5.16, 6.07) 5.03 (4.79, 5.24) 5.44 (5.07, 5.72) 5.55 (5.17, 6.00) 6.01 (5.55, 6.88) 5.88 (5.38, 6.84) 5.40 (5.20, 5.70) 5.10 (5.00, 5.30) 5.30 (5.10, 5.50) 5.40 (5.20, 5.70) 5.70 (5.40, 6.10) 5.70 (5.40, 6.20) 1.31 (0.90, 1.92) 0.78 (0.62, 0.98) 0.86 (0.63, 1.10) 1.42 (0.99, 2.04) 1.55 (1.14, 2.18) 1.43 (0.99, 2.07) 5.09 (4.45, 5.79) 4.65 (4.22, 5.09) 4.73 (4.19, 5.15) 5.28 (4.63, 6.00) 5.04 (4.37, 5.74) 4.71 (3.98, 5.53) 3.05 (2.46, 3.65) 2.61 (2.20, 3.00) 2.77 (2.38, 3.13) 3.21 (2.64, 3.83) 2.92 (2.33, 3.54) 2.61 (2.02, 3.34) 1.29 (1.06, 1.58) 1.66 (1.40, 1.91) 1.53 (1.29, 1.76) 1.24 (1.03, 1.53) 1.24 (1.03, 1.54) 1.23 (1.03, 1.53) 42.00 (40.00, 45.00) 43.00 (41.00, 45.00) 43.00 (41.00, 45.00) 42.00 (40.00, 45.00) 42.00 (40.00, 44.00) 41.00 (39.00, 44.00) 22.00 (17.00, 30.00) 17.00 (14.00, 21.48) 18.00 (15.00, 24.00) 23.00 (17.00, 32.00) 24.00 (18.00, 35.00) 21.00 (16.00, 28.00) 23.00 (19.00, 27.00) 21.00 (18.00, 24.00) 21.00 (18.00, 25.00) 22.00 (19.00, 27.00) 26.00 (22.00, 34.00) 23.00 (19.00, 28.00) 21.00 (15.00, 33.00) 14.00 (11.00, 18.00) 16.00 (12.00, 22.00) 22.00 (16.00, 34.00) 27.00 (18.00, 47.00) 23.00 (16.00, 36.00) 0.36 (0.12, 1.11) 0.10 (0.04, 0.34) 0.24 (0.08, 0.78) 0.38 (0.14, 1.20) 0.48 (0.18, 1.60) 0.46 (0.17, 1.50) 94.09 (80.03, 107.11) 99.14 (89.55, 110.27) 99.68 (88.09, 111.41) 97.18 (84.36, 108.95) 80.02 (65.29, 92.51) 77.15 (59.61, 92.61) 63.10 (28.74, 86.59) 7.78 (5.06, 12.45) 25.32 (14.88, 39.34) 67.68 (37.26, 88.34) 82.07 (68.96, 92.46) 69.69 (37.66, 89.50) 0.93 (0.66, 1.32) 0.82 (0.64, 1.08) 0.87 (0.67, 1.12) 0.82 (0.59, 1.09) 1.62 (1.41, 2.01) 1.45 (1.02, 1.94) 4.31 (3.81, 4.83) 3.44 (3.02, 3.94) 3.86 (3.36, 4.31) 4.38 (3.89, 4.86) 4.56 (4.12, 5.07) 4.50 (4.02, 5.01) 432.44 (354.56, 520.22) 281.41 (238.14, 320.25) 348.05 (298.69, 403.19) 441.55 (370.32, 527.07) 495.24 (440.24, 567.70) 464.92 (391.74, 551.71) 124.34 (98.74, 154.49) 76.56 (65.73, 88.53) 101.02 (85.56, 117.26) 128.68 (104.10, 159.60) 142.12 (122.93, 167.53) 129.54 (106.33, 160.74) 2.56 (2.09, 3.10) 1.66 (1.42, 1.88) 2.07 (1.77, 2.39) 2.60 (2.17, 3.13) 2.94 (2.58, 3.40) 2.76 (2.32, 3.31) 1.35 (0.08, 3.20) −0.83 (−1.13, −0.44) 0.22 (−0.33, 0.88) 1.44 (0.29, 3.26) 2.74 (1.68, 4.41) 2.01 (0.68, 4.03) 47.54 (40.72, 54.60) 35.17 (30.32, 40.11) 40.63 (34.75, 45.87) 48.03 (41.77, 54.57) 52.51 (46.75, 59.14) 51.55 (44.90, 58.56) 3.52 (3.07, 3.98) 2.73 (2.33, 3.12) 3.03 (2.66, 3.46) 3.54 (3.13, 3.98) 3.86 (3.44, 4.32) 3.79 (3.34, 4.26) Abbreviations: CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin A1c; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; CVD, cardiovascular disease; CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index. Continuous variables are expressed as median (interquartile range) and categorical variables as frequency (percentage) Associations of CTI-anthropometric indices with mortality risk During a median follow-up period of 11.42 years (interquartile range, 4.17–15.92 years), 772 incident cases of cardiovascular mortality and 2,424 incident cases of all-cause mortality were observed in participants with CKLM syndrome. As shown in Fig. 1A–B and Supplementary Figure S2–S3, Kaplan‒Meier curve analyses indicated participants in the highest quartile of CTI-anthropometric indices had significantly the highest incidences of cardiovascular deaths and all-cause deaths (Log-rank p < 0.001).Fig. 1(A-B) Kaplan-Meier curves for cardiovascular mortality and all-cause mortality according to CTI-ABSI quartiles in individuals with CKLM syndrome. (C-D) Dose-response relationship between CTI-ABSI and cardiovascular mortality as well as all-cause mortality in individuals with CKLM syndrome. Hazard ratios were adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index; CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome (A-B) Kaplan-Meier curves for cardiovascular mortality and all-cause mortality according to CTI-ABSI quartiles in individuals with CKLM syndrome. (C-D) Dose-response relationship between CTI-ABSI and cardiovascular mortality as well as all-cause mortality in individuals with CKLM syndrome. Hazard ratios were adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index; CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome Multivariable Cox proportional hazard models were constructed to evaluate the associations between CTI-anthropometric indices and mortality risk. As illustrated in Table 2, elevated CTI-anthropometric indices were significantly associated with increased risks of cardiovascular mortality and all-cause mortality. After full adjustment for potential confounders, CTI-ABSI as a continuous variable showed the strongest positive association with cardiovascular mortality (HR 1.34, 95% CI 1.13–1.60, p < 0.001) and all-cause mortality (HR 1.40, 95% CI 1.28–1.53, p < 0.001). In categorical analysis, the top three indices linked to cardiovascular mortality were CTI-WWI (HR for Q4 vs. Q1 1.76, 95% CI 1.25–2.47, p = 0.001), CTI-WC (HR for Q4 vs. Q1 1.63, 95% CI 1.17–2.27, p = 0.004), and CTI-ABSI (HR for Q4 vs. Q1 1.62, 95% CI 1.15–2.27, p = 0.005). In contrast, the top three indices related to all-cause mortality were CTI-WWI (HR for Q4 vs. Q1 1.74, 95% CI 1.46–2.07, p < 0.001), CTI-ABSI (HR for Q4 vs. Q1 1.63, 95% CI 1.36–1.95, p < 0.001), and CTI (HR for Q4 vs. Q1 1.63, 95% CI 1.38–1.92, p < 0.001).Table 2Association of CTI-anthropometric indices with mortality risk via Cox proportional hazards modelCTI-anthropometric indicesCrude ModelaAdjusted ModelaCrude ModelbAdjusted ModelbHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueCTI (1-SD increase)1.82(1.62–2.05)<0.0011.25(1.06–1.48)0.0081.80(1.67–1.93)<0.0011.31(1.20–1.42)<0.001CTI (Quartiles) Q1ReferenceReferenceReferenceReference Q22.11(1.57–2.82)<0.0011.25(0.93–1.68)0.1351.75(1.49–2.06)<0.0011.12(0.95–1.31)0.180 Q32.01(1.56–2.59)<0.0011.10(0.86–1.40)0.4492.08(1.76–2.46)<0.0011.21(1.05–1.41)0.009 Q43.40(2.60–4.45)<0.0011.60(1.18–2.17)0.0033.11(2.63–3.68)<0.0011.63(1.38–1.92)<0.001CTI-WC (1-SD increase)1.00(1.00–1.00)<0.0011.00(1.00–1.00)<0.0011.00(1.00–1.00)<0.0011.00(1.00–1.00)<0.001CTI-WC (Quartiles) Q1ReferenceReferenceReferenceReference Q22.44(1.80–3.29)<0.0011.28(0.96–1.70)0.0921.92(1.67–2.19)<0.0011.15(0.99–1.34)0.077 Q32.60(1.96–3.46)<0.0011.07(0.80–1.42)0.6512.20(1.86–2.61)<0.0011.08(0.93–1.26)0.312 Q43.98(2.89–5.49)<0.0011.63(1.17–2.27)0.0042.97(2.52–3.49)<0.0011.47(1.24–1.74)<0.001CTI-BMI (1-SD increase)1.01(1.00–1.01)<0.0011.00(1.00–1.01)0.0391.00(1.00–1.01)<0.0011.00(1.00–1.00)<0.001CTI-BMI (Quartiles) Q1ReferenceReferenceReferenceReference Q21.82(1.39–2.39)<0.0011.09(0.83–1.44)0.5391.67(1.48–1.89)<0.0011.11(0.97–1.27)0.121 Q31.68(1.26–2.23)<0.0010.91(0.68–1.21)0.5061.53(1.31–1.79)<0.0010.96(0.84–1.10)0.541 Q42.34(1.75–3.12)<0.0011.55(1.10–2.18)0.0111.87(1.59–2.21)<0.0011.42(1.20–1.68)<0.001CTI-WHtR (1-SD increase)1.85(1.66–2.07)<0.0011.31(1.08–1.58)0.0061.71(1.60–1.82)<0.0011.26(1.16–1.38)<0.001CTI-WHtR (Quartiles) Q1ReferenceReferenceReferenceReference Q22.09(1.55–2.83)<0.0011.10(0.81–1.50)0.5491.98(1.74–2.26)<0.0011.18(1.02–1.37)0.023 Q32.60(1.95–3.48)<0.0011.04(0.77–1.41)0.7772.41(2.05–2.83)<0.0011.15(0.97–1.35)0.102 Q43.98(2.97–5.33)<0.0011.59(1.12–2.25)0.0093.18(2.73–3.70)<0.0011.51(1.28–1.79)<0.001CTI-BRI (1-SD increase)1.14(1.11–1.18)<0.0011.06(1.01–1.12)0.0201.11(1.09–1.13)<0.0011.04(1.02–1.07)0.002CTI-BRI (Quartiles) Q1ReferenceReferenceReferenceReference Q21.38(1.03–1.85)0.0290.83(0.61–1.11)0.2091.24(1.07–1.44)0.0040.85(0.72–1.01)0.061 Q32.13(1.62–2.82)<0.0010.89(0.66–1.20)0.4491.78(1.51–2.09)<0.0010.90(0.76–1.07)0.252 Q43.10(2.32–4.14)<0.0011.21(0.87–1.68)0.2542.28(1.95–2.67)<0.0011.10(0.93–1.29)0.264CTI-WWI (1-SD increase)1.06(1.06–1.07)<0.0011.02(1.01–1.03)<0.0011.06(1.05–1.07)<0.0011.02(1.02–1.03)<0.001CTI-WWI (Quartiles) Q1ReferenceReferenceReferenceReference Q22.71(1.97–3.74)<0.0011.37(0.99–1.89)0.0562.20(1.88–2.56)<0.0011.23(1.04–1.45)0.018 Q33.68(2.73–4.96)<0.0011.40(1.05–1.87)0.0232.99(2.52–3.55)<0.0011.32(1.11–1.56)0.002 Q46.03(4.54–8.00)<0.0011.76(1.25–2.47)0.0015.00(4.31–5.79)<0.0011.74(1.46–2.07)<0.001CTI-ABSI (1-SD increase)2.67(2.33–3.05)<0.0011.34(1.13–1.60)<0.0012.56(2.34–2.79)<0.0011.40(1.28–1.53)<0.001CTI-ABSI (Quartiles) Q1ReferenceReferenceReferenceReference Q22.43(1.78–3.33)<0.0011.25(0.89–1.74)0.1971.91(1.63–2.23)<0.0011.08(0.92–1.28)0.339 Q33.67(2.76–4.90)<0.0011.36(1.02–1.82)0.0383.04(2.59–3.57)<0.0011.29(1.08–1.54)0.004 Q46.10(4.53–8.23)<0.0011.62(1.15–2.27)0.0055.21(4.47–6.07)<0.0011.63(1.36–1.95)<0.001a Model for cardiovascular mortality, b Model for all-cause mortality. Crude Model: Non-adjusted. Adjusted Model: Adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index Table 2Association of CTI-anthropometric indices with mortality risk via Cox proportional hazards modelCTI-anthropometric indicesCrude ModelaAdjusted ModelaCrude ModelbAdjusted ModelbHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueCTI (1-SD increase)1.82(1.62–2.05)<0.0011.25(1.06–1.48)0.0081.80(1.67–1.93)<0.0011.31(1.20–1.42)<0.001CTI (Quartiles) Q1ReferenceReferenceReferenceReference Q22.11(1.57–2.82)<0.0011.25(0.93–1.68)0.1351.75(1.49–2.06)<0.0011.12(0.95–1.31)0.180 Q32.01(1.56–2.59)<0.0011.10(0.86–1.40)0.4492.08(1.76–2.46)<0.0011.21(1.05–1.41)0.009 Q43.40(2.60–4.45)<0.0011.60(1.18–2.17)0.0033.11(2.63–3.68)<0.0011.63(1.38–1.92)<0.001CTI-WC (1-SD increase)1.00(1.00–1.00)<0.0011.00(1.00–1.00)<0.0011.00(1.00–1.00)<0.0011.00(1.00–1.00)<0.001CTI-WC (Quartiles) Q1ReferenceReferenceReferenceReference Q22.44(1.80–3.29)<0.0011.28(0.96–1.70)0.0921.92(1.67–2.19)<0.0011.15(0.99–1.34)0.077 Q32.60(1.96–3.46)<0.0011.07(0.80–1.42)0.6512.20(1.86–2.61)<0.0011.08(0.93–1.26)0.312 Q43.98(2.89–5.49)<0.0011.63(1.17–2.27)0.0042.97(2.52–3.49)<0.0011.47(1.24–1.74)<0.001CTI-BMI (1-SD increase)1.01(1.00–1.01)<0.0011.00(1.00–1.01)0.0391.00(1.00–1.01)<0.0011.00(1.00–1.00)<0.001CTI-BMI (Quartiles) Q1ReferenceReferenceReferenceReference Q21.82(1.39–2.39)<0.0011.09(0.83–1.44)0.5391.67(1.48–1.89)<0.0011.11(0.97–1.27)0.121 Q31.68(1.26–2.23)<0.0010.91(0.68–1.21)0.5061.53(1.31–1.79)<0.0010.96(0.84–1.10)0.541 Q42.34(1.75–3.12)<0.0011.55(1.10–2.18)0.0111.87(1.59–2.21)<0.0011.42(1.20–1.68)<0.001CTI-WHtR (1-SD increase)1.85(1.66–2.07)<0.0011.31(1.08–1.58)0.0061.71(1.60–1.82)<0.0011.26(1.16–1.38)<0.001CTI-WHtR (Quartiles) Q1ReferenceReferenceReferenceReference Q22.09(1.55–2.83)<0.0011.10(0.81–1.50)0.5491.98(1.74–2.26)<0.0011.18(1.02–1.37)0.023 Q32.60(1.95–3.48)<0.0011.04(0.77–1.41)0.7772.41(2.05–2.83)<0.0011.15(0.97–1.35)0.102 Q43.98(2.97–5.33)<0.0011.59(1.12–2.25)0.0093.18(2.73–3.70)<0.0011.51(1.28–1.79)<0.001CTI-BRI (1-SD increase)1.14(1.11–1.18)<0.0011.06(1.01–1.12)0.0201.11(1.09–1.13)<0.0011.04(1.02–1.07)0.002CTI-BRI (Quartiles) Q1ReferenceReferenceReferenceReference Q21.38(1.03–1.85)0.0290.83(0.61–1.11)0.2091.24(1.07–1.44)0.0040.85(0.72–1.01)0.061 Q32.13(1.62–2.82)<0.0010.89(0.66–1.20)0.4491.78(1.51–2.09)<0.0010.90(0.76–1.07)0.252 Q43.10(2.32–4.14)<0.0011.21(0.87–1.68)0.2542.28(1.95–2.67)<0.0011.10(0.93–1.29)0.264CTI-WWI (1-SD increase)1.06(1.06–1.07)<0.0011.02(1.01–1.03)<0.0011.06(1.05–1.07)<0.0011.02(1.02–1.03)<0.001CTI-WWI (Quartiles) Q1ReferenceReferenceReferenceReference Q22.71(1.97–3.74)<0.0011.37(0.99–1.89)0.0562.20(1.88–2.56)<0.0011.23(1.04–1.45)0.018 Q33.68(2.73–4.96)<0.0011.40(1.05–1.87)0.0232.99(2.52–3.55)<0.0011.32(1.11–1.56)0.002 Q46.03(4.54–8.00)<0.0011.76(1.25–2.47)0.0015.00(4.31–5.79)<0.0011.74(1.46–2.07)<0.001CTI-ABSI (1-SD increase)2.67(2.33–3.05)<0.0011.34(1.13–1.60)<0.0012.56(2.34–2.79)<0.0011.40(1.28–1.53)<0.001CTI-ABSI (Quartiles) Q1ReferenceReferenceReferenceReference Q22.43(1.78–3.33)<0.0011.25(0.89–1.74)0.1971.91(1.63–2.23)<0.0011.08(0.92–1.28)0.339 Q33.67(2.76–4.90)<0.0011.36(1.02–1.82)0.0383.04(2.59–3.57)<0.0011.29(1.08–1.54)0.004 Q46.10(4.53–8.23)<0.0011.62(1.15–2.27)0.0055.21(4.47–6.07)<0.0011.63(1.36–1.95)<0.001a Model for cardiovascular mortality, b Model for all-cause mortality. Crude Model: Non-adjusted. Adjusted Model: Adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index Association of CTI-anthropometric indices with mortality risk via Cox proportional hazards model 1.82 (1.62–2.05) 1.25 (1.06–1.48) 1.80 (1.67–1.93) 1.31 (1.20–1.42) 2.11 (1.57–2.82) 1.25 (0.93–1.68) 1.75 (1.49–2.06) 1.12 (0.95–1.31) 2.01 (1.56–2.59) 1.10 (0.86–1.40) 2.08 (1.76–2.46) 1.21 (1.05–1.41) 3.40 (2.60–4.45) 1.60 (1.18–2.17) 3.11 (2.63–3.68) 1.63 (1.38–1.92) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 2.44 (1.80–3.29) 1.28 (0.96–1.70) 1.92 (1.67–2.19) 1.15 (0.99–1.34) 2.60 (1.96–3.46) 1.07 (0.80–1.42) 2.20 (1.86–2.61) 1.08 (0.93–1.26) 3.98 (2.89–5.49) 1.63 (1.17–2.27) 2.97 (2.52–3.49) 1.47 (1.24–1.74) 1.01 (1.00–1.01) 1.00 (1.00–1.01) 1.00 (1.00–1.01) 1.00 (1.00–1.00) 1.82 (1.39–2.39) 1.09 (0.83–1.44) 1.67 (1.48–1.89) 1.11 (0.97–1.27) 1.68 (1.26–2.23) 0.91 (0.68–1.21) 1.53 (1.31–1.79) 0.96 (0.84–1.10) 2.34 (1.75–3.12) 1.55 (1.10–2.18) 1.87 (1.59–2.21) 1.42 (1.20–1.68) 1.85 (1.66–2.07) 1.31 (1.08–1.58) 1.71 (1.60–1.82) 1.26 (1.16–1.38) 2.09 (1.55–2.83) 1.10 (0.81–1.50) 1.98 (1.74–2.26) 1.18 (1.02–1.37) 2.60 (1.95–3.48) 1.04 (0.77–1.41) 2.41 (2.05–2.83) 1.15 (0.97–1.35) 3.98 (2.97–5.33) 1.59 (1.12–2.25) 3.18 (2.73–3.70) 1.51 (1.28–1.79) 1.14 (1.11–1.18) 1.06 (1.01–1.12) 1.11 (1.09–1.13) 1.04 (1.02–1.07) 1.38 (1.03–1.85) 0.83 (0.61–1.11) 1.24 (1.07–1.44) 0.85 (0.72–1.01) 2.13 (1.62–2.82) 0.89 (0.66–1.20) 1.78 (1.51–2.09) 0.90 (0.76–1.07) 3.10 (2.32–4.14) 1.21 (0.87–1.68) 2.28 (1.95–2.67) 1.10 (0.93–1.29) 1.06 (1.06–1.07) 1.02 (1.01–1.03) 1.06 (1.05–1.07) 1.02 (1.02–1.03) 2.71 (1.97–3.74) 1.37 (0.99–1.89) 2.20 (1.88–2.56) 1.23 (1.04–1.45) 3.68 (2.73–4.96) 1.40 (1.05–1.87) 2.99 (2.52–3.55) 1.32 (1.11–1.56) 6.03 (4.54–8.00) 1.76 (1.25–2.47) 5.00 (4.31–5.79) 1.74 (1.46–2.07) 2.67 (2.33–3.05) 1.34 (1.13–1.60) 2.56 (2.34–2.79) 1.40 (1.28–1.53) 2.43 (1.78–3.33) 1.25 (0.89–1.74) 1.91 (1.63–2.23) 1.08 (0.92–1.28) 3.67 (2.76–4.90) 1.36 (1.02–1.82) 3.04 (2.59–3.57) 1.29 (1.08–1.54) 6.10 (4.53–8.23) 1.62 (1.15–2.27) 5.21 (4.47–6.07) 1.63 (1.36–1.95) a Model for cardiovascular mortality, b Model for all-cause mortality. Crude Model: Non-adjusted. Adjusted Model: Adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index Further, a competing risk analysis via the Fine-Gray competing risk model was conducted, with non-cardiovascular mortality treated as a competing event. As shown in Supplementary Table S8, the most significant association with cardiovascular mortality was observed for CTI-WHtR (HR 1.21, 95% CI 1.06–1.39, p = 0.004), followed by CTI-ABSI (HR 1.19, 95% CI 1.04–1.37, p = 0.014). Other CTI-anthropometric indices also showed consistent positive associations. These results highlight the robust, independent association between elevated CTI-anthropometric indices, particularly CTI-ABSI, and mortality risk. Dose–response relationships of CTI-anthropometric indices and mortality risk The dose–response relationships between CTI-anthropometric indices and mortality risk were further investigated using RCS regression models. As shown in Fig. 1C–D and Supplementary Figure S4–S5, the fully adjusted RCS plots revealed distinct patterns for the association between different CTI-anthropometric indices and mortality risk. Specifically, CTI-ABSI exhibited a linear positive association with both cardiovascular mortality and all-cause mortality (P for non-linear = 0.883 and 0.938, respectively). In addition, CTI-WC and CTI-BRI demonstrated non-linear associations with both cardiovascular mortality and all-cause mortality (P for non-linear < 0.05). Comparison of the predictive value of CTI-anthropometric indices Based on the significant associations observed above, ROC curve analysis was used to evaluate and compare the predictive ability of CTI-anthropometric indices for cardiovascular mortality and all-cause mortality at 1-, 5-, and 10-year time points. As shown in Fig. 2, among the CTI-anthropometric indices, CTI-ABSI consistently exhibited the preferred discriminative ability across all prediction time points and outcomes. For the prediction of cardiovascular mortality, the AUC values of CTI-ABSI were 0.72, 0.72, and 0.69 at 1, 5, and 10 years, respectively. In predicting all-cause mortality, the AUC values of CTI-ABSI at 1, 5, and 10 years were 0.73, 0.72, and 0.68, respectively. These findings indicated that CTI-ABSI outperforms other CTI-anthropometric indices in predicting both short- and long-term mortality risk.Fig. 2ROC curves and AUC values (with 95% confidence band) of the CTI-anthropometric indices for predicting cardiovascular (A, C, E) and all-cause mortality (B, D, F) at 1-, 5-, and 10-year. ROC, receiver operating characteristic; AUC, the area under the curve; CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index ROC curves and AUC values (with 95% confidence band) of the CTI-anthropometric indices for predicting cardiovascular (A, C, E) and all-cause mortality (B, D, F) at 1-, 5-, and 10-year. ROC, receiver operating characteristic; AUC, the area under the curve; CTI, C-reactive protein-triglyceride glucose index; CTI-WC, C-reactive protein-triglyceride glucose index combined with waist circumference; CTI-BMI, C-reactive protein-triglyceride glucose index combined with body mass index; CTI-WHtR, C-reactive protein-triglyceride glucose index combined with waist-to-height ratio; CTI-BRI, C-reactive protein-triglyceride glucose index combined with body roundness index; CTI-WWI, C-reactive protein-triglyceride glucose index combined with weight-adjusted waist index; CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index Subgroup and sensitivity analyses for CTI-ABSI To evaluate the consistency of the association between CTI-ABSI and mortality risk across different populations, subgroup analyses were performed. As shown in Fig. 3, the High-CTI-ABSI group was consistently associated with an increased risk of cardiovascular mortality and all-cause mortality across subgroups stratified by age, gender, race, FIB-4, hypertension, diabetes, dyslipidemia, and CKLM syndrome. Notably, the effect of CTI-ABSI on both cardiovascular mortality (interaction p = 0.004) and all-cause mortality (interaction p < 0.001) was more pronounced among participants younger than 60 years, which remained significant after Bonferroni correction for eight subgroup interaction tests (adjusted threshold p < 0.006).Fig. 3Subgroup analysis of the association between CTI-ABSI and cardiovascular mortality as well as all-cause mortality in individuals with CKLM syndrome. Hazard ratios were adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. *represents deaths/total number of participants. CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index; FIB-4, fibrosis-4 index; CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome Subgroup analysis of the association between CTI-ABSI and cardiovascular mortality as well as all-cause mortality in individuals with CKLM syndrome. Hazard ratios were adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. *represents deaths/total number of participants. CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index; FIB-4, fibrosis-4 index; CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome To assess the robustness of the association between CTI-ABSI and mortality risk, we performed five sensitivity analyses. As shown in Table 3, the direction of the associations between CTI-ABSI and both cardiovascular mortality and all-cause mortality remained consistent with the primary analysis across all sensitivity analyses. These findings indicate that the positive association between CTI-ABSI and mortality risk is robust and not substantially influenced by different exclusion criteria.Table 3Sensitivity analysis of the association between CTI-ABSI and mortality risk in individuals with CKLM syndromeCTI-ABSICrude ModelaAdjusted ModelaCrude ModelbAdjusted ModelbHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueExcluding deaths occurring or censored within the first 2 years of follow-up1-SD increase2.65(2.30–3.05)<0.0011.31(1.10–1.55)0.0022.52(2.29–2.76)<0.0011.33(1.22–1.46)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.62(1.92–3.57)<0.0011.34(0.97–1.85)0.0761.94(1.66–2.26)<0.0011.10(0.93–1.30)0.276 Q33.91(2.92–5.21)<0.0011.45(1.09–1.93)0.0113.07(2.61–3.60)<0.0011.30(1.08–1.56)0.004 Q46.09(4.52–8.21)<0.0011.61(1.17–2.23)0.0045.02(4.30–5.86)<0.0011.55(1.28–1.87)<0.001Excluding participants with a history of CVD1-SD increase3.01(2.48–3.64)<0.0011.62(1.26–2.09)<0.0012.63(2.34–2.94)<0.0011.45(1.28–1.66)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.63(1.75–3.95)<0.0011.47(0.96–2.26)0.0791.81(1.49–2.21)<0.0011.10(0.89–1.35)0.370 Q34.37(2.77–6.91)<0.0011.83(1.15–2.92)0.0112.89(2.33–3.59)<0.0011.34(1.07–1.68)0.011 Q48.16(5.20–12.8)<0.0012.39(1.45–3.93)<0.0015.40(4.42–6.61)<0.0011.77(1.38–2.28)<0.001Excluding participants with a history of cancer1-SD increase2.67(2.32–3.07)<0.0011.33(1.10–1.61)0.0032.54(2.32–2.78)<0.0011.35(1.22–1.50)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.39(1.68–3.42)<0.0011.25(0.86–1.83)0.2461.79(1.51–2.12)<0.0011.03(0.85–1.25)0.767 Q33.63(2.59–5.11)<0.0011.37(0.98–1.92)0.0662.86(2.39–3.43)<0.0011.23(1.02–1.49)0.027 Q46.06(4.34–8.46)<0.0011.63(1.11–2.39)0.0135.05(4.25–6.01)<0.0011.59(1.29–1.95)<0.001Excluding participants aged over 75 years1-SD increase2.72(2.29–3.23)<0.0011.38(1.09–1.74)0.0072.63(2.37–2.93)<0.0011.46(1.31–1.64)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.81(1.97–4.01)<0.0011.52(1.02–2.27)0.0421.96(1.63–2.35)<0.0011.18(0.96–1.45)0.116 Q33.74(2.57–5.42)<0.0011.56(1.04–2.34)0.0323.00(2.48–3.63)<0.0011.44(1.17–1.76)<0.001 Q46.59(4.46–9.74)<0.0011.83(1.14–2.93)0.0125.46(4.55–6.55)<0.0011.83(1.47–2.28)<0.001Excluding participants with missing any key covariates1-SD increase2.87(2.30–3.58)<0.0011.34(1.01–1.78)0.0442.73(2.37–3.14)<0.0011.37(1.16–1.63)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q21.88(1.17–3.01)0.0090.98(0.63–1.52)0.9241.78(1.39–2.28)<0.0010.99(0.76–1.29)0.959 Q33.18(2.05–4.96)<0.0011.25(0.81–1.94)0.3172.88(2.25–3.68)<0.0011.20(0.91–1.58)0.207 Q45.09(3.32–7.80)<0.0011.34(0.84–2.15)0.2144.94(3.87–6.29)<0.0011.49(1.09–2.05)0.012a Model for cardiovascular mortality, b Model for all-cause mortality. Crude Model: Non-adjusted. Adjusted Model: Adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index; CVD, cardiovascular disease; CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome Table 3Sensitivity analysis of the association between CTI-ABSI and mortality risk in individuals with CKLM syndromeCTI-ABSICrude ModelaAdjusted ModelaCrude ModelbAdjusted ModelbHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueHR(95% CI)P-valueExcluding deaths occurring or censored within the first 2 years of follow-up1-SD increase2.65(2.30–3.05)<0.0011.31(1.10–1.55)0.0022.52(2.29–2.76)<0.0011.33(1.22–1.46)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.62(1.92–3.57)<0.0011.34(0.97–1.85)0.0761.94(1.66–2.26)<0.0011.10(0.93–1.30)0.276 Q33.91(2.92–5.21)<0.0011.45(1.09–1.93)0.0113.07(2.61–3.60)<0.0011.30(1.08–1.56)0.004 Q46.09(4.52–8.21)<0.0011.61(1.17–2.23)0.0045.02(4.30–5.86)<0.0011.55(1.28–1.87)<0.001Excluding participants with a history of CVD1-SD increase3.01(2.48–3.64)<0.0011.62(1.26–2.09)<0.0012.63(2.34–2.94)<0.0011.45(1.28–1.66)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.63(1.75–3.95)<0.0011.47(0.96–2.26)0.0791.81(1.49–2.21)<0.0011.10(0.89–1.35)0.370 Q34.37(2.77–6.91)<0.0011.83(1.15–2.92)0.0112.89(2.33–3.59)<0.0011.34(1.07–1.68)0.011 Q48.16(5.20–12.8)<0.0012.39(1.45–3.93)<0.0015.40(4.42–6.61)<0.0011.77(1.38–2.28)<0.001Excluding participants with a history of cancer1-SD increase2.67(2.32–3.07)<0.0011.33(1.10–1.61)0.0032.54(2.32–2.78)<0.0011.35(1.22–1.50)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.39(1.68–3.42)<0.0011.25(0.86–1.83)0.2461.79(1.51–2.12)<0.0011.03(0.85–1.25)0.767 Q33.63(2.59–5.11)<0.0011.37(0.98–1.92)0.0662.86(2.39–3.43)<0.0011.23(1.02–1.49)0.027 Q46.06(4.34–8.46)<0.0011.63(1.11–2.39)0.0135.05(4.25–6.01)<0.0011.59(1.29–1.95)<0.001Excluding participants aged over 75 years1-SD increase2.72(2.29–3.23)<0.0011.38(1.09–1.74)0.0072.63(2.37–2.93)<0.0011.46(1.31–1.64)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q22.81(1.97–4.01)<0.0011.52(1.02–2.27)0.0421.96(1.63–2.35)<0.0011.18(0.96–1.45)0.116 Q33.74(2.57–5.42)<0.0011.56(1.04–2.34)0.0323.00(2.48–3.63)<0.0011.44(1.17–1.76)<0.001 Q46.59(4.46–9.74)<0.0011.83(1.14–2.93)0.0125.46(4.55–6.55)<0.0011.83(1.47–2.28)<0.001Excluding participants with missing any key covariates1-SD increase2.87(2.30–3.58)<0.0011.34(1.01–1.78)0.0442.73(2.37–3.14)<0.0011.37(1.16–1.63)<0.001Quartiles Q1ReferenceReferenceReferenceReference Q21.88(1.17–3.01)0.0090.98(0.63–1.52)0.9241.78(1.39–2.28)<0.0010.99(0.76–1.29)0.959 Q33.18(2.05–4.96)<0.0011.25(0.81–1.94)0.3172.88(2.25–3.68)<0.0011.20(0.91–1.58)0.207 Q45.09(3.32–7.80)<0.0011.34(0.84–2.15)0.2144.94(3.87–6.29)<0.0011.49(1.09–2.05)0.012a Model for cardiovascular mortality, b Model for all-cause mortality. Crude Model: Non-adjusted. Adjusted Model: Adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index; CVD, cardiovascular disease; CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome Sensitivity analysis of the association between CTI-ABSI and mortality risk in individuals with CKLM syndrome 2.65 (2.30–3.05) 1.31 (1.10–1.55) 2.52 (2.29–2.76) 1.33 (1.22–1.46) 2.62 (1.92–3.57) 1.34 (0.97–1.85) 1.94 (1.66–2.26) 1.10 (0.93–1.30) 3.91 (2.92–5.21) 1.45 (1.09–1.93) 3.07 (2.61–3.60) 1.30 (1.08–1.56) 6.09 (4.52–8.21) 1.61 (1.17–2.23) 5.02 (4.30–5.86) 1.55 (1.28–1.87) 3.01 (2.48–3.64) 1.62 (1.26–2.09) 2.63 (2.34–2.94) 1.45 (1.28–1.66) 2.63 (1.75–3.95) 1.47 (0.96–2.26) 1.81 (1.49–2.21) 1.10 (0.89–1.35) 4.37 (2.77–6.91) 1.83 (1.15–2.92) 2.89 (2.33–3.59) 1.34 (1.07–1.68) 8.16 (5.20–12.8) 2.39 (1.45–3.93) 5.40 (4.42–6.61) 1.77 (1.38–2.28) 2.67 (2.32–3.07) 1.33 (1.10–1.61) 2.54 (2.32–2.78) 1.35 (1.22–1.50) 2.39 (1.68–3.42) 1.25 (0.86–1.83) 1.79 (1.51–2.12) 1.03 (0.85–1.25) 3.63 (2.59–5.11) 1.37 (0.98–1.92) 2.86 (2.39–3.43) 1.23 (1.02–1.49) 6.06 (4.34–8.46) 1.63 (1.11–2.39) 5.05 (4.25–6.01) 1.59 (1.29–1.95) 2.72 (2.29–3.23) 1.38 (1.09–1.74) 2.63 (2.37–2.93) 1.46 (1.31–1.64) 2.81 (1.97–4.01) 1.52 (1.02–2.27) 1.96 (1.63–2.35) 1.18 (0.96–1.45) 3.74 (2.57–5.42) 1.56 (1.04–2.34) 3.00 (2.48–3.63) 1.44 (1.17–1.76) 6.59 (4.46–9.74) 1.83 (1.14–2.93) 5.46 (4.55–6.55) 1.83 (1.47–2.28) 2.87 (2.30–3.58) 1.34 (1.01–1.78) 2.73 (2.37–3.14) 1.37 (1.16–1.63) 1.88 (1.17–3.01) 0.98 (0.63–1.52) 1.78 (1.39–2.28) 0.99 (0.76–1.29) 3.18 (2.05–4.96) 1.25 (0.81–1.94) 2.88 (2.25–3.68) 1.20 (0.91–1.58) 5.09 (3.32–7.80) 1.34 (0.84–2.15) 4.94 (3.87–6.29) 1.49 (1.09–2.05) a Model for cardiovascular mortality, b Model for all-cause mortality. Crude Model: Non-adjusted. Adjusted Model: Adjusted for age, gender, race, education level, family poverty income ratio, smoking status, drinking status, physical activity time, systolic blood pressure, glycosylated hemoglobin A1c, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, cancer, antihypertensive agents, lipid-lowering agents, and antihyperglycemic agents. CTI-ABSI, C-reactive protein-triglyceride glucose index combined with a body shape index; CVD, cardiovascular disease; CKLM syndrome, cardiovascular-kidney-liver-metabolic syndrome Discussion To our knowledge, this is among the first studies to investigate the relationships between CTI-anthropometric indices and mortality risk in individuals with CKLM syndrome. Our results demonstrated that CTI-anthropometric indices were positively associated with the risks of both cardiovascular mortality and all-cause mortality in patients with CKLM syndrome. By comparing the predictive efficacy of CTI-anthropometric indices, we found that CTI-ABSI outperformed the other CTI-anthropometric indices in predicting mortality risk. Subgroup and sensitivity analyses further confirmed the robustness of the results of CTI-ABSI. These findings lay the foundation for applying CTI-ABSI to identify individuals with CKLM syndrome who are at high risk of mortality, which will help us adopt more effective risk management strategies to improve the overall prognosis for these populations. Recently, the risk stratification and management of CKM syndrome have attracted much attention. Several studies have demonstrated that biomarkers such as the TyG, estimated glucose disposal rate, metabolic score for insulin resistance, and CTI have predictive utility for adverse cardiovascular events in individuals with CKM syndrome [8, 23–25]. MASLD is closely associated with increased incidences of diabetes, CKD, and CVD [26]. Previous studies applied the expansion of the CKM framework to CKLM syndrome, emphasizing the common clinical and pathophysiological features of CKM syndrome and MASLD [2, 3]. However, a limited study focused on the early risk stratification of CKLM syndrome. In this study, we assessed the utility of CTI in combination with body composition indices to elucidate the mortality risk associated with CKLM syndrome. These findings provide preliminary insights into the risk profiles pertaining to CKLM syndrome. As an emerging surrogate biomarker of insulin resistance and systemic inflammation, CTI has garnered increasing attention for its potential to predict adverse outcomes. Initially, CTI was developed to assess the risk of mortality among cancer survivors [27, 28]. Accumulating evidence supports the predictive utility of CTI in cardiometabolic disease, often outperforming the TyG alone in terms of predictive accuracy [29, 30]. Recently, Ou et al. found that elevated CTI was positively and nonlinearly associated with the risk of CVD and linearly related to an increased risk of all-cause mortality in individuals with CKM stages 0–3 [8]. Moreover, a cohort study revealed that CTI exhibits a stronger association with the presence of MASLD, and a significant positive correlation between CTI and mortality risk was observed among participants with MASLD [10]. Compared with the TyG-related indices, CTI significantly improved risk stratification, offering a more reliable basis for the clinical assessment of mortality risk in the elderly population [31]. This prognostic value has also been demonstrated in patients with decompensated heart failure, where CTI independently predicted in‑hospital and 1‑year mortality [32]. In the present study, we demonstrated that CTI was positively linearly associated with cardiovascular mortality and all-cause mortality in individuals with CKLM syndrome, and it had moderate prognostic value for predicting both short- and long-term survival outcomes. Obesity, especially visceral obesity, is regarded as a core driver in the development of CKLM syndrome [4]. BMI is the most widely used clinical metric for measuring adiposity, but it cannot distinguish between visceral and subcutaneous fat accumulation. Alternative anthropometric indicators, such as the WHtR, BRI, WWI, and ABSI, have emerged from recent obesity phenotyping advancements, all of which are closely linked to visceral fat accumulation and CVD risk [33–36]. The integration of CTI with anthropometric indices has emerged as a validated approach to improve discriminative ability. This approach has been effectively implemented to enhance the early risk identification or stratification of hypertension, CKD, stroke, and CVD [18, 30, 37, 38]. In this study, our results demonstrated that CTI-anthropometric indices were positively associated with the risks of both cardiovascular mortality and all-cause mortality in patients with CKLM syndrome. Further, CTI-ABSI demonstrated the preferred AUC value among the CTI-anthropometric indices, highlighting its better predictive capability and a stronger associative relationship with mortality risk. This indicates that CTI-ABSI may help identify high-risk CKLM patients earlier, thereby facilitating timely intervention. Meanwhile, CTI-ABSI integrates a marker of visceral obesity, capturing the detrimental effects of central obesity beyond what traditional metabolic indicators alone can provide. Yang et al. demonstrated that the TyG-ABSI is a standalone predictor of mortality in individuals with MASLD, surpassing the predictive capabilities of traditional TyG-related indices [39]. Further RCS analyses revealed a positive linear relationship between CTI-ABSI and mortality risk in individuals with CKLM syndrome. In addition, we identified an inflection point at 3.57, beyond which mortality risk increased markedly, underscoring the clinical importance of monitoring CTI-ABSI levels and intervening before values exceed this critical threshold. Recent findings from a meta-analysis demonstrated a linear connection between TyG-ABSI and cardiovascular mortality [40]. These results imply that the combined assessment of CTI and ABSI has implications for predicting adverse events in individuals with CKLM syndrome. Subgroup analyses revealed that the association between CTI-ABSI and mortality risk was consistent across multiple subgroups, with no significant effect modification observed for most stratified variables except for age. Among participants aged < 60 years, an increased CTI-ABSI was more strongly related to cardiovascular mortality and all-cause mortality. We speculated that this phenomenon may be associated with the peak prevalence of obesity manifesting before the age of 60 [41]. Moreover, the mortality risk among the elderly population has markedly increased, with age emerging as the predominant determinant of mortality. This shift has consequently diminished the relative significance of metabolic indicators. Notably, a cohort study utilizing NHANES data indicated that the rising burden of CKLM multimorbidity is influenced by socioeconomic factors, underscoring the critical need to incorporate social determinants into risk stratification [5]. The interaction between the CTI-ABSI of CKLM syndrome and social risk factors, such as economic status, education, food safety, and marital status, needs further investigation to personalize risk stratification. In addition, a trend of effect modification was observed in the CKLM staging concerning cardiovascular mortality. The CKLM staging serves as a pivotal phase in the progression from metabolic dysfunction to severe cardiovascular events, underscoring the necessity for early intervention. Despite the correlation observed in our study, the exact mechanism by which CTI-ABSI is most strongly associated with cardiovascular mortality and all-cause mortality remains unclear. The improved predictive performance of mortality risk observed for CTI-ABSI in CKLM syndrome may be ascribed to the distinct pathophysiological interaction among insulin resistance, systemic inflammation, and visceral obesity. ABSI serves as an important metric for assessing visceral adipose tissue, the excess or dysfunction of which can drive insulin resistance and systemic inflammation by secreting pro-inflammatory cytokines (e.g., TNF-α, IL-6) and free fatty acids [42, 43]. Insulin resistance may augment gluconeogenesis while diminishing hepatic glycogen synthesis, consequently elevating glucose production and release, which in turn exacerbates insulin resistance through mechanisms involving inflammation, oxidative stress, endoplasmic reticulum stress, and lipotoxicity [44, 45]. These processes ultimately impair endothelial function and expedite the development of CVD. Therefore, the CTI-ABSI is closely related to the pathophysiology of CKLM syndrome, which may account for the association. More studies are required to shed light on the underlying mechanisms. Nevertheless, there are several limitations in our study. First, since this study is a cohort study, whether CTI-anthropometric indices play a causal role in mortality risk among individuals with CKLM syndrome remains to be further investigated. Second, the definition of several variables in this study relied on self-reported questionnaires, which may lead to some bias. Third, given that our study was based on a single cohort mainly composed of Non-Hispanic Whites in the United States, external validation in other racial/ethnic or regional populations is warranted to confirm our findings. Fourth, the inherent or residual confounding factors may be inevitable, although we have ruled out their possible influence through multivariable adjustment and sensitivity analysis. Finally, although this study evaluated the relationship between the single baseline CTI-anthropometric indices and mortality risk, there is a potential for risk misclassification. Furthermore, the association between the dynamics of the CTI-anthropometric indices and mortality risk remains uncertain and warrants further investigation. Conclusion Elevated CTI-anthropometric indices were independently associated with increased mortality risk in individuals with CKLM syndrome, with CTI-ABSI emerging as the preferred predictor of mortality risk. These findings provide an approach for enhancing risk discrimination and stratification in individuals with CKLM syndrome. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1